US20030026782A1
(en)
*
|
1995-02-07 |
2003-02-06 |
Arthur M. Krieg |
Immunomodulatory oligonucleotides
|
US6207646B1
(en)
*
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
UA67760C2
(uk)
*
|
1997-12-11 |
2004-07-15 |
Міннесота Майнінг Енд Мануфакчурінг Компані |
Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
|
EP1176966B1
(fr)
|
1999-04-12 |
2013-04-03 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Un oligodesoxynucleotide et son emploi pour induire une reponse immunitaire
|
US6331539B1
(en)
*
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
US20030129251A1
(en)
|
2000-03-10 |
2003-07-10 |
Gary Van Nest |
Biodegradable immunomodulatory formulations and methods for use thereof
|
US6664264B2
(en)
*
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6545016B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Amide substituted imidazopyridines
|
UA74852C2
(en)
*
|
2000-12-08 |
2006-02-15 |
3M Innovative Properties Co |
Urea-substituted imidazoquinoline ethers
|
US6677347B2
(en)
*
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamido ether substituted imidazoquinolines
|
US6660735B2
(en)
*
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Urea substituted imidazoquinoline ethers
|
US6664265B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
AU2006216669A1
(en)
*
|
2000-12-08 |
2006-08-31 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
US6667312B2
(en)
*
|
2000-12-08 |
2003-12-23 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US7255868B2
(en)
*
|
2001-06-21 |
2007-08-14 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same—I
|
US7321033B2
(en)
*
|
2001-11-27 |
2008-01-22 |
Anadys Pharmaceuticals, Inc. |
3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
|
MXPA04012199A
(es)
|
2002-06-07 |
2005-02-25 |
3M Innovative Properties Co |
Imidazopiridinas sustituidas con eter.
|
BR0314761A
(pt)
*
|
2002-09-27 |
2005-07-26 |
Sumitomo Pharma |
Composto de adenina e seu uso
|
PT2241325E
(pt)
*
|
2002-10-29 |
2012-04-12 |
Coley Pharm Gmbh |
Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
|
US7091214B2
(en)
|
2002-12-20 |
2006-08-15 |
3M Innovative Properties Co. |
Aryl substituted Imidazoquinolines
|
US20040265351A1
(en)
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
EP1617845A4
(fr)
*
|
2003-04-28 |
2006-09-20 |
3M Innovative Properties Co |
Compositions et methodes d'induction de recepteurs opoides
|
MXPA06001674A
(es)
*
|
2003-08-12 |
2006-05-12 |
3M Innovative Properties Co |
Compuestos que contienen imidazo hidroxilamina-sustituidos.
|
WO2005018555A2
(fr)
*
|
2003-08-14 |
2005-03-03 |
3M Innovative Properties Company |
Modificateurs de la reponse immunitaire a modification lipidique
|
CA2536249A1
(fr)
*
|
2003-08-25 |
2005-03-10 |
3M Innovative Properties Company |
Administration de composes modificateurs de la reponse immunitaire
|
BRPI0413998A
(pt)
|
2003-08-27 |
2006-11-07 |
3M Innovative Properties Co |
imidazoquinolinas arilóxi e arilalquilenóxi substituìdas
|
AU2004270201A1
(en)
*
|
2003-09-05 |
2005-03-17 |
3M Innovative Properties Company |
Treatment for CD5+ B cell lymphoma
|
AU2004275876B2
(en)
*
|
2003-09-25 |
2011-03-31 |
Coley Pharmaceutical Gmbh |
Nucleic acid-lipophilic conjugates
|
MY146124A
(en)
|
2003-10-03 |
2012-06-29 |
3M Innovative Properties Co |
Pyrazolopyridines and analogs thereof
|
US7544697B2
(en)
*
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
US20090075980A1
(en)
*
|
2003-10-03 |
2009-03-19 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and Analogs Thereof
|
MXPA06003705A
(es)
*
|
2003-10-03 |
2006-06-20 |
3M Innovative Properties Co |
Imidazoquinolinas sustituidas con alcoxi.
|
CA2545825A1
(fr)
|
2003-11-14 |
2005-06-02 |
3M Innovative Properties Company |
Composes d'un anneau d'imidazo substitue par hydroxylamine
|
WO2005048933A2
(fr)
*
|
2003-11-14 |
2005-06-02 |
3M Innovative Properties Company |
Composes d'un anneau d'imidazo substitues par oxime
|
WO2005051324A2
(fr)
*
|
2003-11-25 |
2005-06-09 |
3M Innovative Properties Company |
Hydroxylamine, et imidazoquinoleines, et imidazopyridines et imidazonaphtyridine substitues d'oxime
|
US8691837B2
(en)
|
2003-11-25 |
2014-04-08 |
3M Innovative Properties Company |
Substituted imidazo ring systems and methods
|
US20050226878A1
(en)
*
|
2003-12-02 |
2005-10-13 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
TW200533352A
(en)
*
|
2003-12-04 |
2005-10-16 |
3M Innovative Properties Co |
Sulfone substituted imidazo ring ethers
|
US7888349B2
(en)
*
|
2003-12-29 |
2011-02-15 |
3M Innovative Properties Company |
Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds
|
US8802853B2
(en)
*
|
2003-12-29 |
2014-08-12 |
3M Innovative Properties Company |
Arylalkenyl and arylalkynyl substituted imidazoquinolines
|
AU2004312508A1
(en)
*
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
|
AU2005228150A1
(en)
*
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
US8012964B2
(en)
|
2004-03-26 |
2011-09-06 |
Dainippon Sumitomo Pharma Co., Ltd. |
9-substituted 8-oxoadenine compound
|
CA2564855A1
(fr)
*
|
2004-04-28 |
2005-10-28 |
3M Innovative Properties Company |
Compositions et methodes pour vaccination muqueuse
|
US20050267145A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
US20080015184A1
(en)
*
|
2004-06-14 |
2008-01-17 |
3M Innovative Properties Company |
Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
|
WO2005123080A2
(fr)
*
|
2004-06-15 |
2005-12-29 |
3M Innovative Properties Company |
Imidazoquinolines et imidazonaphthyridines substituees par un heterocyclyle contenant un azote
|
US8541438B2
(en)
|
2004-06-18 |
2013-09-24 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
AU2005283085B2
(en)
*
|
2004-06-18 |
2012-06-21 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
US8026366B2
(en)
*
|
2004-06-18 |
2011-09-27 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
US7897609B2
(en)
*
|
2004-06-18 |
2011-03-01 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
WO2006065280A2
(fr)
*
|
2004-06-18 |
2006-06-22 |
3M Innovative Properties Company |
Composes a noyau imidazo a substitutif d'isoxazole, de dihydroisoxazole et d'oxadiazole
|
US20060045886A1
(en)
*
|
2004-08-27 |
2006-03-02 |
Kedl Ross M |
HIV immunostimulatory compositions
|
US20090270443A1
(en)
*
|
2004-09-02 |
2009-10-29 |
Doris Stoermer |
1-amino imidazo-containing compounds and methods
|
CA2578975A1
(fr)
|
2004-09-02 |
2006-03-16 |
3M Innovative Properties Company |
Systemes cycliques de 2-amino 1h imidazo et procedes correspondants
|
PL1789042T3
(pl)
*
|
2004-09-02 |
2012-09-28 |
3M Innovative Properties Co |
Układy pierścieni 1-alkoksy 1H-imidazo i sposoby
|
US20070243215A1
(en)
*
|
2004-10-08 |
2007-10-18 |
Miller Richard L |
Adjuvant for Dna Vaccines
|
JP2008523076A
(ja)
*
|
2004-12-08 |
2008-07-03 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫調節性の組成物、合剤、および方法
|
US20080188513A1
(en)
*
|
2004-12-30 |
2008-08-07 |
Taked Pharmaceutical Company Limited |
1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Ethanesulfonate and 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Methanesulfonate
|
SI1830876T1
(sl)
*
|
2004-12-30 |
2015-08-31 |
Meda Ab |
Uporaba imikvimoda za zdravljenje kožnih metastaz, ki izhajajo iz rakavega tumorja dojke
|
AU2005322898B2
(en)
|
2004-12-30 |
2011-11-24 |
3M Innovative Properties Company |
Chiral fused (1,2)imidazo(4,5-c) ring compounds
|
US8436176B2
(en)
*
|
2004-12-30 |
2013-05-07 |
Medicis Pharmaceutical Corporation |
Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
|
EP1831221B1
(fr)
|
2004-12-30 |
2012-08-08 |
3M Innovative Properties Company |
Composes chiraux 1,2 imidazo 4,5-c substitues a noyau fusionne
|
EP1844201B1
(fr)
*
|
2005-02-04 |
2016-08-24 |
3M Innovative Properties Company |
Formulations des gel aqueux contenant des modificateurs de reponse immunitaire
|
ES2475728T3
(es)
|
2005-02-09 |
2014-07-11 |
3M Innovative Properties Company |
Tiazoloquinolinas y tiazolonaftiridinas sustituidas con alcoxi
|
EP1877056A2
(fr)
|
2005-02-09 |
2008-01-16 |
Coley Pharmaceutical Group, Inc. |
Composes cycliques thiazoloý4,5-c¨a substitution oxime et hydroxylamine et procedes associés
|
JP2008532933A
(ja)
|
2005-02-11 |
2008-08-21 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
置換イミダゾキノリン類および置換イミダゾナフチリジン類
|
CA2597587A1
(fr)
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Composes cycliques imidazo[4,5-c] substitues par oxime et hydroxylamine et procedes associes
|
JP2008531567A
(ja)
|
2005-02-23 |
2008-08-14 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
ヒドロキシアルキル置換イミダゾキノリン化合物および方法
|
AU2006216799A1
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Hydroxyalkyl substituted imidazonaphthyridines
|
WO2006091647A2
(fr)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Methode d'induction preferentielle de la biosynthese d'interferon
|
AU2006223634A1
(en)
|
2005-02-23 |
2006-09-21 |
Coley Pharmaceutical Group, Inc. |
Hydroxyalkyl substituted imidazoquinolines
|
MX2007011112A
(es)
|
2005-03-14 |
2007-11-07 |
Graceway Pharmaceuticals Llc |
Metodo para tratar queratosis actinica.
|
EP1869043A2
(fr)
|
2005-04-01 |
2007-12-26 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridine-1,4-diamines et analogues associes
|
US7943636B2
(en)
|
2005-04-01 |
2011-05-17 |
3M Innovative Properties Company |
1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
|
CA2605808A1
(fr)
*
|
2005-04-25 |
2006-11-02 |
3M Innovative Properties Company |
Compositions immunostimulantes
|
MX2007013780A
(es)
*
|
2005-05-04 |
2008-02-05 |
Pfizer Ltd |
Derivados 2 amido-6-amino-8-oxo purina como moduladores del receptor como tipo peaje (toll) para el tratamiento del cancer y las infecciones virales tal como la hepatitis c.
|
CA2615626A1
(fr)
*
|
2005-07-18 |
2007-01-25 |
Novartis Ag |
Modele petit animal pour une replication hcv
|
WO2007024707A2
(fr)
*
|
2005-08-22 |
2007-03-01 |
The Regents Of The University Of California |
Agonistes tlr
|
ZA200803029B
(en)
*
|
2005-09-09 |
2009-02-25 |
Coley Pharm Group Inc |
Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
|
US8476292B2
(en)
|
2005-09-09 |
2013-07-02 |
3M Innovative Properties Company |
Amide and carbamate derivatives of N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1-dimethylethyl}methanesulfonamide and methods
|
WO2007038720A2
(fr)
*
|
2005-09-27 |
2007-04-05 |
Coley Pharmaceutical Gmbh |
Modulation de reponses immunitaires mediees par tlr, au moyen d'oligonucleotides d'adaptation
|
AU2006311871B2
(en)
|
2005-11-04 |
2011-03-03 |
3M Innovative Properties Company |
Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
|
WO2007056527A2
(fr)
*
|
2005-11-09 |
2007-05-18 |
Cheng Si Yuan (China-International) Hepatitis Research Foundation |
Methodes et agents diagnostiques et therapeutiques
|
ES2345904T3
(es)
|
2005-11-21 |
2010-10-05 |
Anadys Pharmaceuticals, Inc. |
Proceso para preparar 5-amino-3h-tiazolo(4,5-d)pirimidin-2-ona.
|
JP2009528989A
(ja)
*
|
2006-02-17 |
2009-08-13 |
ファイザー・リミテッド |
Tlr7変調剤としての3−デアザプリン誘導体
|
US8951528B2
(en)
|
2006-02-22 |
2015-02-10 |
3M Innovative Properties Company |
Immune response modifier conjugates
|
US8329721B2
(en)
|
2006-03-15 |
2012-12-11 |
3M Innovative Properties Company |
Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
|
JP5167244B2
(ja)
|
2006-04-11 |
2013-03-21 |
ノバルティス アーゲー |
Hcv/hiv阻害剤およびそれらの使用
|
CN101426514A
(zh)
*
|
2006-04-25 |
2009-05-06 |
英特塞尔股份公司 |
Hcv疫苗
|
CA2652349A1
(fr)
*
|
2006-05-15 |
2007-11-22 |
University Of Kentucky Research Foundation |
Stimulation du recepteur de type toll (tlr) utile dans l'angiogenese oculaire et la degenerescence maculaire
|
AR061024A1
(es)
*
|
2006-05-22 |
2008-07-30 |
Novartis Ag |
Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona.
|
WO2007142755A2
(fr)
*
|
2006-05-31 |
2007-12-13 |
The Regents Of The University Of California |
Analogues de la purine
|
AU2007260828B2
(en)
*
|
2006-06-22 |
2013-03-07 |
Anadys Pharmaceuticals, Inc. |
Prodrugs of 5-amino-3-(3'-deoxy-beta-D-ribofuranosyl)-thiazolo[4,5-d] pyrimidin-2,7-dione
|
WO2008004948A1
(fr)
*
|
2006-07-05 |
2008-01-10 |
Astrazeneca Ab |
Dérivés de la 8-oxoadénine agissant comme modulateurs de tlr7
|
WO2008008432A2
(fr)
*
|
2006-07-12 |
2008-01-17 |
Coley Pharmaceutical Group, Inc. |
Composés à cycle [1,2] imidazo [4,5-c] fusionné chiral substitué et procédés correspondants
|
DE602007012881D1
(en)
|
2006-07-18 |
2011-04-14 |
Anadys Pharmaceuticals Inc |
Carbonat- und carbamat-prodrugs von thiazolo ä4,5-dü-pyrimidinen
|
WO2008030511A2
(fr)
|
2006-09-06 |
2008-03-13 |
Coley Pharmaceuticial Group, Inc. |
3, 4, 6, 7-tétrahydro-5h-1, 2a, 4a, 8-tétraazacyclopenta[cd]phénalènes substitués
|
BRPI0717741A2
(pt)
*
|
2006-10-17 |
2014-04-08 |
Anadys Pharmaceuticals Inc |
Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
|
TW200831105A
(en)
*
|
2006-12-14 |
2008-08-01 |
Astrazeneca Ab |
Novel compounds
|
US20080149123A1
(en)
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
EP2115140B8
(fr)
|
2007-01-31 |
2017-01-25 |
Chongxi Yu |
Promédicaments hydrosolubles à charge positive de 1H-imidazo[4,5-c]quinolin-4-amines et composés associés a taux éléves de pénétration cutanée
|
BRPI0807196A2
(pt)
|
2007-02-07 |
2014-06-03 |
Univ California |
Método para prevenir ou inibir uma infecção bacteriana, vacina, composto, e, método para prevenir, tratar ou inibir a asma
|
TW200843779A
(en)
*
|
2007-02-19 |
2008-11-16 |
Smithkline Beecham Corp |
Compounds
|
ATE530549T1
(de)
*
|
2007-03-19 |
2011-11-15 |
Astrazeneca Ab |
9-substituierte 8-oxoadeninverbindungen als modulatoren des toll-like-receptor (tlr7)
|
PT2132209E
(pt)
*
|
2007-03-19 |
2014-04-15 |
Astrazeneca Ab |
Compostos de 8-oxo-adenina substituídos na posição 9, como moduladores do recetor de tipo ¿toll¿ (tlr7)
|
TW200902018A
(en)
*
|
2007-03-20 |
2009-01-16 |
Dainippon Sumitomo Pharma Co |
Novel adenine compound
|
JPWO2008114819A1
(ja)
*
|
2007-03-20 |
2010-07-08 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
US8436178B2
(en)
*
|
2007-05-08 |
2013-05-07 |
Astrazeneca Ab |
Imidazoquinolines with immuno-modulating properties
|
WO2009026292A1
(fr)
*
|
2007-08-20 |
2009-02-26 |
Anadys Pharmaceuticals, Inc. |
Procédés de dosage pour le traitement de pathologies
|
PE20091236A1
(es)
|
2007-11-22 |
2009-09-16 |
Astrazeneca Ab |
Derivados de pirimidina como immunomoduladores de tlr7
|
UY31531A1
(es)
*
|
2007-12-17 |
2009-08-03 |
|
Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
|
EA201001264A1
(ru)
*
|
2008-02-07 |
2011-04-29 |
Дзе Регентс Оф Дзе Юниверсити Оф Калифорния |
Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
|
KR101616396B1
(ko)
|
2008-08-11 |
2016-04-28 |
글락소스미스클라인 엘엘씨 |
신규의 아데닌 유도체
|
UA103195C2
(uk)
|
2008-08-11 |
2013-09-25 |
Глаксосмитклайн Ллк |
Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
|
US8802684B2
(en)
|
2008-08-11 |
2014-08-12 |
Glaxosmithkline Llc |
Adenine derivatives
|
EP2326646B1
(fr)
|
2008-08-11 |
2013-07-31 |
GlaxoSmithKline LLC |
Dérivés de purine destinés à être utilisés pour le traitement de maladies allergiques, inflammatoires et infectieuses
|
CA2738970A1
(fr)
*
|
2008-10-31 |
2010-05-06 |
Moberg Derma Ab |
Composition topique comprenant une combinaison d'au moins deux agents de penetration
|
GB0820698D0
(en)
*
|
2008-11-12 |
2008-12-17 |
Ludwig Inst Cancer Res |
Uses of immunomodulators
|
ES2481040T3
(es)
|
2008-12-09 |
2014-07-29 |
Coley Pharmaceutical Group, Inc. |
Oligonucleótidos inmunoestimulantes
|
US8552165B2
(en)
*
|
2008-12-09 |
2013-10-08 |
Heather Davis |
Immunostimulatory oligonucleotides
|
CN103497192B
(zh)
|
2008-12-09 |
2015-09-23 |
吉里德科学公司 |
Toll样受体调节剂
|
WO2010091265A1
(fr)
*
|
2009-02-05 |
2010-08-12 |
Yale University |
Composés et procédés destinés au traitement d'une encéphalite virale
|
WO2010088924A1
(fr)
|
2009-02-06 |
2010-08-12 |
Telormedix Sa |
Compositions pharmaceutiques comprenant des imidazoquinolines (amines) et des dérivés de celles-ci appropriés pour une administration locale
|
BRPI1008383A2
(pt)
|
2009-02-11 |
2016-02-23 |
Univ California |
composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
GB0908772D0
(en)
*
|
2009-05-21 |
2009-07-01 |
Astrazeneca Ab |
New salts 756
|
KR20120030436A
(ko)
|
2009-05-21 |
2012-03-28 |
아스트라제네카 아베 |
신규한 피리미딘 유도체 및 암 및 추가의 질병의 치료에서의 이의 용도
|
JP2013512859A
(ja)
*
|
2009-12-03 |
2013-04-18 |
大日本住友製薬株式会社 |
トール様受容体(tlr)を介して作用するイミダゾキノリン
|
WO2011098451A1
(fr)
|
2010-02-10 |
2011-08-18 |
Glaxosmithkline Llc |
Dérivés de purine et leurs utilisations pharmaceutiques
|
WO2011101332A1
(fr)
|
2010-02-16 |
2011-08-25 |
Proyecto De Biomedicina Cima, S.L. |
Compositions basées sur le domaine extracellulaire a de fibronectine pour le traitement d'un mélanome
|
US9050319B2
(en)
|
2010-04-30 |
2015-06-09 |
Telormedix, Sa |
Phospholipid drug analogs
|
AU2011247358B2
(en)
|
2010-04-30 |
2014-10-30 |
Urogen Pharma Ltd. |
Phospholipid drug analogs
|
US9242980B2
(en)
|
2010-08-17 |
2016-01-26 |
3M Innovative Properties Company |
Lipidated immune response modifier compound compositions, formulations, and methods
|
EA201390532A1
(ru)
|
2010-10-08 |
2013-09-30 |
Новартис Аг |
Композиции сульфамидых ингибиторов ns3, содержащие витамин е
|
ES2575688T3
(es)
|
2010-12-16 |
2016-06-30 |
Sumitomo Dainippon Pharma Co., Ltd. |
Derivado de imidazo[4,5-c]quinolin-1-ilo útil en terapia
|
DK2651943T3
(en)
|
2010-12-17 |
2017-06-06 |
Sumitomo Dainippon Pharma Co Ltd |
purine derivatives
|
BR122019023564B1
(pt)
|
2011-04-08 |
2021-06-22 |
Janssen Sciences Ireland Uc |
Formas de dosagem contendo derivados de pirimidina para o tratamento de infecções virais
|
EP2717919B1
(fr)
|
2011-06-03 |
2016-08-03 |
3M Innovative Properties Company |
Lieurs hétérobifonctionnels comportant de segments de polyéthylène glycol et conjugués modificateurs de réponse immunitaire obtenus à partir de ceux-ci
|
WO2012167081A1
(fr)
|
2011-06-03 |
2012-12-06 |
3M Innovative Properties Company |
Hydrazino 1h-imidazoquinoléine-4-amines et conjugués obtenus à partir de celles-ci
|
RU2631482C2
(ru)
|
2011-07-22 |
2017-09-22 |
ГЛАКСОСМИТКЛАЙН ЭлЭлСи |
Композиция
|
ES2529143B1
(es)
|
2011-10-21 |
2015-10-26 |
Abbvie Inc. |
Combinación de al menos dos agentes antivirales de acción directa, ribavirina pero no interferón para uso de tratamiento del vhc
|
PT107925A
(pt)
|
2011-10-21 |
2014-12-03 |
Abbvie Inc |
Tratamento de combinação de daa (eg. com abt-072 ou abt-333) para utilização no tratamento de hcv
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
PT2776439T
(pt)
|
2011-11-09 |
2018-11-02 |
Janssen Sciences Ireland Uc |
Derivados de purina para o tratamento de infeções virais
|
AR090699A1
(es)
|
2012-04-18 |
2014-12-03 |
Biocryst Pharm Inc |
Compuestos inhibidores de la actividad de la arn polimerasa viral
|
KR102194585B1
(ko)
|
2012-05-18 |
2020-12-23 |
다이닛본 스미토모 세이야꾸 가부시끼가이샤 |
카르복실산 화합물
|
WO2014004704A1
(fr)
*
|
2012-06-26 |
2014-01-03 |
California Institute Of Technology |
Systèmes et procédés pour mettre en œuvre des roues dentées en verre métallique brut à échelle macroscopique
|
PT2872515T
(pt)
|
2012-07-13 |
2016-07-27 |
Janssen Sciences Ireland Uc |
Purinas macrocíclicas para o tratamento de infeções virais
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
CA2880576A1
(fr)
|
2012-08-24 |
2014-02-27 |
Glaxosmithkline Llc |
Composes pyrazolopyrimidine
|
HUE037064T2
(hu)
|
2012-10-10 |
2018-08-28 |
Janssen Sciences Ireland Uc |
Pirrolo[3,2-d]-pirimidin származékok vírusos fertõzések és egyéb betegségek kezelésére
|
BR112015011036B1
(pt)
|
2012-11-16 |
2022-02-01 |
Janssen Sciences Ireland Uc |
Derivados de 2-amino-quinazolina substituídos heterocíclicos, composição farmacêutica
|
EP2922547B1
(fr)
|
2012-11-20 |
2017-03-08 |
Glaxosmithkline LLC |
Nouveaux composés
|
PT2922549T
(pt)
|
2012-11-20 |
2017-09-01 |
Glaxosmithkline Llc |
Novos compostos
|
BR112015011447A2
(pt)
|
2012-11-20 |
2017-07-11 |
Glaxosmithkline Llc |
composto da fórmula i, composição farmacêutica e de vacina, e, uso de um composto
|
CN105189468B
(zh)
|
2013-02-21 |
2018-10-30 |
爱尔兰詹森科学公司 |
用于治疗病毒性感染的2-氨基嘧啶衍生物
|
PL2978429T3
(pl)
*
|
2013-03-29 |
2017-08-31 |
Janssen Sciences Ireland Uc |
Deazapurynony makrocykliczne do leczenia infekcji wirusowych
|
CN105377833B
(zh)
|
2013-05-24 |
2018-11-06 |
爱尔兰詹森科学公司 |
用于治疗病毒感染和另外的疾病的吡啶酮衍生物
|
US9452217B2
(en)
|
2013-06-22 |
2016-09-27 |
Nitor Therapeutics |
Methods for potentiating immune response for the treatment of infectious diseases and cancer
|
DK3030563T3
(da)
|
2013-06-27 |
2017-11-20 |
Janssen Sciences Ireland Uc |
Pyrrolo-[3,2-d]-pyrimidin-derivater til behandling af virale infektioner og andre sygdomme
|
WO2015014815A1
(fr)
|
2013-07-30 |
2015-02-05 |
Janssen R&D Ireland |
Dérivés de thiéno[3,2-d]pyrimidines destinés au traitement d'infections virales
|
CN105899539B
(zh)
|
2014-01-10 |
2021-11-09 |
博笛生物科技有限公司 |
用于免疫疗法的化合物和组合物
|
HUE049656T2
(hu)
*
|
2014-04-22 |
2020-10-28 |
Hoffmann La Roche |
4-amino-imidazo-kinolin vegyületek
|
AU2015280234B2
(en)
*
|
2014-06-24 |
2021-04-01 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
CN105233291A
(zh)
*
|
2014-07-09 |
2016-01-13 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
JP6760919B2
(ja)
|
2014-07-09 |
2020-09-23 |
バーディー バイオファーマシューティカルズ インコーポレイテッド |
腫瘍を治療するための抗pd−l1組み合わせ
|
WO2016007765A1
(fr)
|
2014-07-11 |
2016-01-14 |
Gilead Sciences, Inc. |
Modulateurs de récepteurs de type toll pour le traitement du vih
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
UY36298A
(es)
|
2014-09-16 |
2016-04-29 |
Gilead Science Inc |
Formas sólidas de un modulador del receptor tipo toll
|
SI3230298T1
(sl)
|
2014-12-08 |
2021-04-30 |
F. Hoffmann-La Roche Ag |
Spojine 3-substituiranega 5-amino-6H-tiazolo(4,5-d)pirimidin-2,7-diona za zdravljenje ali preprečevanje okužbe z virusom
|
MX370769B
(es)
|
2015-03-16 |
2019-12-20 |
Hoffmann La Roche |
Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsida del vhb.
|
WO2016180691A1
(fr)
|
2015-05-08 |
2016-11-17 |
F. Hoffmann-La Roche Ag |
Nouveaux acides carboxyliques oxathiolane et dérivés pour le traitement et la prophylaxie d'une infection virale
|
WO2016180743A1
(fr)
|
2015-05-12 |
2016-11-17 |
F. Hoffmann-La Roche Ag |
Nouvelle aminothiazolopyrimidinedione substituée pour le traitement et la prophylaxie d'une infection virale
|
KR101729236B1
(ko)
*
|
2015-06-01 |
2017-04-21 |
(주)노터스생명과학 |
Tlr7 항진제를 포함하는 비만 또는 간질환 예방 및 치료용 약학 조성물
|
CN107820498B
(zh)
|
2015-06-30 |
2020-06-19 |
豪夫迈·罗氏有限公司 |
用于治疗和预防病毒感染的取代的氨基噻唑并嘧啶二酮
|
CN115554406A
(zh)
|
2016-01-07 |
2023-01-03 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-cd20组合
|
CN106943598A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技(北京)有限公司 |
用于治疗肿瘤的抗-her2组合
|
CN106943597A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技(北京)有限公司 |
用于治疗肿瘤的抗-egfr组合
|
WO2017184735A1
(fr)
|
2016-04-19 |
2017-10-26 |
Ifm Therapeutics, Inc |
Modulateurs de nlrp3
|
WO2017184746A1
(fr)
|
2016-04-19 |
2017-10-26 |
Ifm Therapeutics, Inc |
Modulateurs de nlrp3
|
WO2017188287A1
(fr)
*
|
2016-04-26 |
2017-11-02 |
大日本住友製薬株式会社 |
Dérivé substitué de purine
|
WO2017189978A1
(fr)
|
2016-04-28 |
2017-11-02 |
Emory University |
Compositions thérapeutiques à base de nucléotides et nucléosides contenant un alcyne et utilisations associées
|
US11697851B2
(en)
|
2016-05-24 |
2023-07-11 |
The Regents Of The University Of California |
Early ovarian cancer detection diagnostic test based on mRNA isoforms
|
WO2018002319A1
(fr)
|
2016-07-01 |
2018-01-04 |
Janssen Sciences Ireland Uc |
Dihydropyranopyrimidines pour le traitement d'infections virales
|
KR20160141683A
(ko)
|
2016-09-21 |
2016-12-09 |
(주)노터스생명과학 |
Tlr7 항진제를 포함하는 비만 또는 간질환 예방 및 치료용 약학 조성물
|
EP3519406B1
(fr)
|
2016-09-29 |
2022-02-23 |
Janssen Sciences Ireland Unlimited Company |
Prodrugs des composés de pyrimidine pour le traitement des infections virales et autres maladies
|
AU2017366621B2
(en)
|
2016-11-28 |
2021-07-29 |
Jiangsu Hengrui Medicine Co., Ltd. |
Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
|
JP7201598B2
(ja)
|
2017-01-06 |
2023-01-10 |
エフ.ホフマン-ラ ロシュ アーゲー |
3位置換5-アミノ-6H-チアゾロ[4,5-d]ピリミジン-2,7-ジオン化合物の製造法
|
KR20170010887A
(ko)
|
2017-01-20 |
2017-02-01 |
(주)노터스생명과학 |
Tlr7 항진제를 포함하는 비만 또는 간질환 예방 및 치료용 약학 조성물
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
WO2018162450A1
(fr)
|
2017-03-06 |
2018-09-13 |
Fundación Para La Investigación Médica Aplicada |
Nouvelles compositions immunostimulatrices comprenant une entité protéine de liaison à l'arn inductible à froid (cirp)-antigène pour l'activation des cellules dendritiques
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
CN110177793B
(zh)
*
|
2017-05-18 |
2021-12-21 |
江苏恒瑞医药股份有限公司 |
杂芳基并吡唑类衍生物、其制备方法及其在医药上的应用
|
US11517567B2
(en)
|
2017-06-23 |
2022-12-06 |
Birdie Biopharmaceuticals, Inc. |
Pharmaceutical compositions
|
WO2019123178A1
(fr)
|
2017-12-20 |
2019-06-27 |
3M Innovative Properties Company |
Composés imidazo [4,5-c]quinoléine à substitution amide ayant un groupe de liaison à chaîne ramifiée destinés à être utilisés en tant que modificateur de la réponse immunitaire
|
CN108558864B
(zh)
*
|
2018-01-30 |
2020-07-03 |
中国医学科学院药用植物研究所 |
一种瑞喹莫德的酰化衍生物及制备方法与应用
|
TW202415645A
(zh)
|
2018-03-01 |
2024-04-16 |
愛爾蘭商健生科學愛爾蘭無限公司 |
2,4-二胺基喹唑啉衍生物及其醫學用途
|
KR20210013624A
(ko)
|
2018-05-25 |
2021-02-04 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
피라졸로헤테로아릴 유도체의 하이드로클로라이드의 결정 형태 및 제조 방법
|
PE20211598A1
(es)
*
|
2018-05-25 |
2021-08-18 |
Primmune Therapeutics Inc |
Agonistas de tlr7
|
CN113194945B
(zh)
*
|
2018-08-23 |
2024-07-23 |
佩勒梅德有限公司 |
环吡酮的抑制hbv核心组装的用途
|
EP3846807B1
(fr)
*
|
2018-09-07 |
2023-08-02 |
Birdie Biopharmaceuticals, Inc. |
Composés d'imidazoquinoléine et leurs utilisations
|
CN114502175A
(zh)
*
|
2019-07-27 |
2022-05-13 |
腾盛博药生物科技有限公司 |
腺苷衍生物和包含其的药物组合物
|
BR112022010165A2
(pt)
|
2019-11-26 |
2022-08-09 |
Primmune Therapeutics Inc |
Agonistas de tlr7
|
EP4076445A1
(fr)
|
2019-12-20 |
2022-10-26 |
Nammi Therapeutics, Inc. |
Compositions liposomales formulées et/ou co-formulées contenant des promédicaments agonistes de récepteurs de type toll (« tlr ») utiles dans le traitement du cancer et méthodes associées
|
US11530218B2
(en)
|
2020-01-20 |
2022-12-20 |
Incyte Corporation |
Spiro compounds as inhibitors of KRAS
|
WO2021231526A1
(fr)
|
2020-05-13 |
2021-11-18 |
Incyte Corporation |
Composés de pyrimidine fusionnés utilisés comme inhibiteurs de kras
|
WO2022047093A1
(fr)
|
2020-08-28 |
2022-03-03 |
Incyte Corporation |
Composés d'imidazole vinylique en tant qu'inhibiteurs de kras
|
WO2022072783A1
(fr)
|
2020-10-02 |
2022-04-07 |
Incyte Corporation |
Composés diones bicycliques en tant qu'inhibiteurs de kras
|
WO2022159877A1
(fr)
|
2021-01-25 |
2022-07-28 |
Brii Biosciences, Inc. |
Polythérapie contre le vih comprenant un dérivé d'adénosine et des inhibiteurs de capside
|
WO2022204112A1
(fr)
|
2021-03-22 |
2022-09-29 |
Incyte Corporation |
Inhibiteurs d'imidazole et triazole kras
|
WO2023049697A1
(fr)
|
2021-09-21 |
2023-03-30 |
Incyte Corporation |
Composés hétéro-tricycliques utilisés en tant qu'inhibiteurs de kras
|
CA3234375A1
(fr)
|
2021-10-01 |
2023-04-06 |
Incyte Corporation |
Inhibiteurs de kras tels que la pyrazoloquinoline
|
AU2022367432A1
(en)
|
2021-10-14 |
2024-05-02 |
Incyte Corporation |
Quinoline compounds as inhibitors of kras
|